Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 3/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | PTGES | O14684 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | LTA4H | P09960 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.59 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.59 |
| ▸ | LOX | P28300 | 1/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.59 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.59 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18346924 | 0.89 | ALOX5 (0.49) | ALOX5CYP1A2PTGESLMNALTA4H | |
| SCHEMBL18346922 | 0.89 | ALOX5 (0.49) | ALOX5CYP1A2PTGESLMNALTA4H | |
| SCHEMBL1809436 | 0.84 | ALOX5 (0.51) | ALOX5CYP1A2PTGESLMNALTA4H | |
| SCHEMBL8895495 | 0.83 | ALOX5 (0.51) | ALOX5CYP1A2PTGESLMNALTA4H | |
| SCHEMBL8933733 | 0.81 | ALOX5 (0.56) | ALOX5CYP1A2PTGESLMNALTA4H | |
| SCHEMBL10701339 | 0.80 | ALOX5 (0.45) | ALOX5CYP1A2PTGESLMNALTA4H | |
| Hydroxyurea SCHEMBL6391315 | 0.79 | ALOX5 (0.57) | ALOX5CYP1A2PTGESLMNALTA4H | |
| Hydroxyurea SCHEMBL9602586 | 0.79 | ALOX5 (0.57) | ALOX5CYP1A2PTGESLMNALTA4H | |
| SCHEMBL8876780 | 0.79 | ALOX5 (0.51) | ALOX5CYP1A2PTGESLMNALTA4H | |
| SCHEMBL1444768 | 0.79 | ALOX5 (0.51) | ALOX5CYP1A2PTGESLMNALTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295713-A1 | COMPOSITIONS AND METHODS FOR IMPROVING SKIN HEALTH AND FOR THE TREATMENT AND PREVENTION OF DISEASES, DISORDERS AND CONDITIONS ASSOCIATED WITH PATHOGENIC MICROBES | DERMBIONT, INC. | 2025-09-25 | — | — | US | disclosed |
| US-12064459-B2 | Compositions and methods for improving skin health and for the treatment and prevention of diseases, disorders and conditions associated with pathogenic microbes | DERMBIONT, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| US-20220160617-A1 | COMPOSITIONS AND METHODS FOR IMPROVING SKIN HEALTH AND FOR THE TREATMENT AND PREVENTION OF DISEASES, DISORDERS AND CONDITIONS ASSOCIATED WITH PATHOGENIC MICROBES | DERMBIONT, INC. | 2022-05-26 | — | — | US | disclosed |
| US-20210386802-A1 | COMPOSITIONS AND METHODS FOR IMPROVING SKIN HEALTH AND FOR THE TREATMENT AND PREVENTION OF DISEASES, DISORDERS AND CONDITIONS ASSOCIATED WITH PATHOGENIC MICROBES | DERMBIONT, INC. | 2021-12-16 | — | — | US | disclosed |
| US-20210361725-A1 | COMPOSITIONS AND METHODS FOR IMPROVING SKIN HEALTH AND FOR THE TREATMENT AND PREVENTION OF DISEASES, DISORDERS AND CONDITIONS ASSOCIATED WITH PATHOGENIC MICROBES | DERMBIONT, INC. | 2021-11-25 | — | — | US | disclosed |
| US-11040077-B2 | Compositions and methods for improving skin health and for the treatment and prevention of diseases, disorders and conditions associated with pathogenic microbes | DERMBIONT, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20200345799-A1 | COMPOSITIONS AND METHODS FOR IMPROVING SKIN HEALTH AND FOR THE TREATMENT AND PREVENTION OF DISEASES, DISORDERS AND CONDITIONS ASSOCIATED WITH PATHOGENIC MICROBES | DERMBIONT, INC. | 2020-11-05 | — | — | US | disclosed |
| WO-2020035729-A1 | TOPICAL OLEAGINOUS COMPOSITIONS | DR. REDDY'S LABORATORIES LTD. (IN) | 2020-02-20 | — | — | WO | disclosed |
| US-20200054654-A1 | TOPICAL OLEAGINOUS COMPOSITIONS | DR. REDDY'S LABORATORIES LTD. (IN) | 2020-02-20 | — | — | US | disclosed |
| US-9670176-B2 | Process for the preparation of zileuton | STRIDES SHASUN LIMITED (IN) | 2017-06-06 | — | — | US | disclosed |
| US-20160376251-A1 | Process for the Preparation of Zileuton | STRIDES SHASUN LIMITED (IN) | 2016-12-29 | — | — | US | disclosed |
| EP-0543855-A1 | USE OF ARYL HYDROXYUREA COMPOUNDS FOR THE TREATMENT OF ATHEROSCLEROSIS | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-06-02 | — | — | EP | disclosed |
| WO-1992003130-A1 | USE OF ARYL HYDROXYUREA COMPOUNDS FOR THE TREATMENT OF ATHEROSCLEROSIS | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160376251-A1 | Process for the Preparation of Zileuton | CYP2B6, UGT1A6, CYP2A6 | ALOX5 124/4885CYP1A2 35/4885PTGES 1385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.